KYMR vs TROW · rev $99.4M vs P/E 12, rev $3.76B
Kymera Therapeutics Inc (KYMR) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Kymera Therapeutics Inc (KYMR) is a biotechnology company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported KYMR revenue for 2026-06-30 was $99.4M. Net income was -$130.4M. KYMR currently screens at market cap $7.39B.
Latest reported TROW revenue for 2026-06-30 was $3.76B. Net income was $1.13B. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
KYMR currently screens at market cap $7.39B. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the KYMR and TROW stock pages for the full models.
Not investment advice.